Penumbra (PEN)

• Market cap: $10.5B
• 1 day: -2.42%
• 5 days: -2.78%
• 1 month: -3.47%
• 3 months: 0.91%
• 6 months: 30.95%
• Year to date: 12.77%
• 1 year: 33.32%
• 5 years: 49.52%
• 10 years: 555.30%
• Sector: Healthcare
• Industry: Medical Devices

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

562% more call options, than puts

Call options by funds: $63.7M | Put options by funds: $9.62M

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

22% more capital invested

Capital invested by funds: $6.8B [Q3] → $8.3B (+$1.5B) [Q4]

12% more funds holding

Funds holding: 329 [Q3] → 367 (+38) [Q4]

0.97% more ownership

Funds ownership: 90.0% [Q3] → 90.97% (+0.97%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 131

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $260 4% downside
• Avg. target: $312 15% upside
• High target: $340 26% upside

10 analyst ratings

• positive: 9 90%
• neutral: 1 10%
• negative: 0 0%

Truist Securities David Rescott 59% 1-year accuracy 10 / 17 met price target	16% upside $315	Buy Maintained	11 Apr 2025
B of A Securities Travis Steed 17% 1-year accuracy 1 / 6 met price target	18% upside $320	Buy Initiated	14 Mar 2025
JP Morgan Robert Marcus 0% 1-year accuracy 0 / 1 met price target	5% upside $285	Overweight Maintained	19 Feb 2025
RBC Capital Shagun Singh 33% 1-year accuracy 22 / 66 met price target	16% upside $313	Outperform Maintained	19 Feb 2025
Canaccord Genuity Jason Mills 56% 1-year accuracy 5 / 9 met price target	26% upside $340	Buy Maintained	19 Feb 2025